Catherine Weiss

664 total citations
40 papers, 502 citations indexed

About

Catherine Weiss is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, Catherine Weiss has authored 40 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pharmacology, 24 papers in Psychiatry and Mental health and 10 papers in Experimental and Cognitive Psychology. Recurrent topics in Catherine Weiss's work include Treatment of Major Depression (24 papers), Schizophrenia research and treatment (20 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers). Catherine Weiss is often cited by papers focused on Treatment of Major Depression (24 papers), Schizophrenia research and treatment (20 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers). Catherine Weiss collaborates with scholars based in Denmark, United States and Canada. Catherine Weiss's co-authors include Emmanuelle Weiller, Mary Hobart, Peter Zhang, Aleksandar Skuban, Michael E. Thase, John Ouyang, Roger S. McIntyre, Christoph U. Correll, John M. Kane and Hans Eriksson and has published in prestigious journals such as Journal of Affective Disorders, Schizophrenia Bulletin and Schizophrenia Research.

In The Last Decade

Catherine Weiss

40 papers receiving 490 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Weiss Denmark	14	370	273	86	77	66	40	502
Pedro Such Denmark	11	307 0.8×	135 0.5×	64 0.7×	73 0.9×	40 0.6×	32	486
Shubhra Mace United Kingdom	9	277 0.7×	125 0.5×	49 0.6×	93 1.2×	55 0.8×	14	467
Azorin Jm France	15	425 1.1×	143 0.5×	74 0.9×	142 1.8×	61 0.9×	64	608
Emmanuelle Weiller Denmark	18	521 1.4×	429 1.6×	184 2.1×	150 1.9×	51 0.8×	35	777
J. N. Beuzen France	5	368 1.0×	246 0.9×	86 1.0×	69 0.9×	56 0.8×	5	511
W. Chrzanowski Poland	7	413 1.1×	126 0.5×	49 0.6×	96 1.2×	110 1.7×	11	497
Philippe Bouhours France	11	329 0.9×	131 0.5×	74 0.9×	70 0.9×	88 1.3×	20	481
Michael D. Teehan Canada	12	312 0.8×	87 0.3×	51 0.6×	119 1.5×	68 1.0×	22	526
Ahsan Y. Khan United States	10	188 0.5×	154 0.6×	124 1.4×	59 0.8×	28 0.4×	25	467
Cedric O’Gorman United States	13	450 1.2×	82 0.3×	84 1.0×	107 1.4×	78 1.2×	31	609

Countries citing papers authored by Catherine Weiss

Since Specialization

Citations

This map shows the geographic impact of Catherine Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Weiss more than expected).

Fields of papers citing papers by Catherine Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Weiss. The network helps show where Catherine Weiss may publish in the future.

Co-authorship network of co-authors of Catherine Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Weiss. A scholar is included among the top collaborators of Catherine Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Weiss. Catherine Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Newcomer, John W., et al.. (2023). Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder. The Journal of Clinical Psychiatry. 84(5). 3 indexed citations

Thase, Michael E., Zahinoor Ismail, Catherine Weiss, et al.. (2023). Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR). Journal of Psychiatric Research. 161. 132–139. 5 indexed citations

Weiss, Catherine, et al.. (2022). Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews. Journal of Patient-Reported Outcomes. 6(1). 111–111. 8 indexed citations

McIntyre, Roger S., et al.. (2022). Patient-reported outcome measures for life engagement in mental health: a systematic review. Journal of Patient-Reported Outcomes. 6(1). 62–62. 30 indexed citations

Marder, Stephen R., et al.. (2021). Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophrenia Bulletin Open. 2(1). sgab014–sgab014. 6 indexed citations

Tandon, Rajiv, William R. Lenderking, Catherine Weiss, et al.. (2020). The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Annals of General Psychiatry. 19(1). 42–42. 48 indexed citations

Newcomer, John W., et al.. (2019). Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole. The Journal of Clinical Psychiatry. 80(6). 6 indexed citations

Thase, Michael E., et al.. (2019). Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opinion on Pharmacotherapy. 20(15). 1907–1916. 19 indexed citations

Weiss, Catherine, et al.. (2019). P.690 Impact of second-generation antipsychotic side effects on functioning from a schizophrenia patient perspective: European perspective of a global patient-centered survey. European Neuropsychopharmacology. 29. S466–S466. 1 indexed citations

10.

Weiss, Catherine, Emmanuelle Weiller, Ross A. Baker, et al.. (2018). The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder. International Clinical Psychopharmacology. 33(5). 255–260. 21 indexed citations

11.

Correll, Christoph U., Catherine Weiss, Mary Hobart, et al.. (2018). Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectrums. 24(5). 507–517. 13 indexed citations

12.

Mago, Rajnish, Andrea Fagiolini, Emmanuelle Weiller, & Catherine Weiss. (2018). Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder. BMC Psychiatry. 18(1). 33–33. 21 indexed citations

13.

Hobart, Mary, et al.. (2018). Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. The International Journal of Neuropsychopharmacology. 22(3). 173–179. 16 indexed citations

14.

Thase, Michael E., Emmanuelle Weiller, Peter Zhang, Catherine Weiss, & Roger S. McIntyre. (2018). Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatric Disease and Treatment. Volume 15. 37–45. 20 indexed citations

15.

Nelson, J. Craig, Emmanuelle Weiller, Peter Zhang, Catherine Weiss, & Mary Hobart. (2017). Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies. Journal of Affective Disorders. 227. 103–108. 12 indexed citations

16.

Weiller, Emmanuelle, et al.. (2017). Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatric Disease and Treatment. Volume 14. 103–115. 12 indexed citations

17.

Marder, Stephen R., Mette Krog Josiassen, Peter Zhang, et al.. (2016). Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatrica. 29(5). 278–290. 29 indexed citations

18.

Correll, Christoph U., Aleksandar Skuban, Mary Hobart, et al.. (2016). Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophrenia Research. 174(1-3). 82–92. 44 indexed citations

19.

McIntyre, Roger S., Emmanuelle Weiller, Peter Zhang, & Catherine Weiss. (2016). Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. Journal of Affective Disorders. 201. 116–123. 28 indexed citations

20.

Marder, S.R., et al.. (2016). An interventional, multi-center, randomized, double-blind, placebo-controlled, active reference, flexible dose study of brexpiprazole in adults with acute schizophrenia. European Psychiatry. 33(S1). S99–S99. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact